A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.
暂无分享,去创建一个
Jason J. Z. Liao | S. Jagannath | S. Lonial | J. Liao | R. Rifkin | T. Facon | J. San-Miguel | R. LeBlanc | S. Usmani | M. Cavo | L. Karlin | Kenshi Suzuki | F. Schjesvold | M. Farooqui | H. Yimer | N. Takezako | P. Marinello | R. McCroskey | R. Ghori | A. O. Rocafiguera